AbbVie generated Q2 2026 total net revenues of nearly $17.0 billion, up 10.2% on an operational basis and beating internal expectations by $300 million behind double-digit growth in Skyrizi, Renvok, and neuroscience.
Core Signals
Revenue Growth & Demand: Operational net sales increased 10.2% year-over-year to $17.0 billion, driven by combined Skyrizi and Renvok operational gains exceeding 20%.
Bullish Signals
Full-year net revenue guidance was raised by $300 million to $67.6 billion due to operational outperformance across Skyrizi, Renvok, and neuroscience.
Risk Signals
Full-year adjusted EPS guidance absorbed 14 cents of anticipated net transaction dilution from the Apogee acquisition along with $200 million in extra net interest expense.
Q&A Signals
Repeated analyst topics: Analysts focused heavily on competitive threats from oral immunology treatments, clinical design strategies in hidradenitis suppurativa, and oncology ADC platform differentiation.
Key Investor Debate
The primary debate among equity analysts centers on whether Skyrizi and Renvok can maintain high operational growth as new oral mechanisms enter psoriasis and dermatology, and how AbbVie will defend Skyrizi post-2033 as composition of matter patents expire.
Analyst Takeaway
AbbVie continues to execute a clean therapeutic replacement story, smoothly transitioning revenue away from legacy products like Humira and Imbruvica toward blockbuster expansion in Skyrizi, Renvok, Vraylar, and Vylev.
Those are the opening lines. The full read covers the whole earnings transcript: every
bullish and bearish signal, what analysts pressed hardest on, and where management
answered vaguely — each with the quote behind it. Every line sourced.
Ask about AbbVie's earnings, or other S&P 500 earnings calls
Ask across the corpus, instead of reading one call at a time. Scope it to AbbVie, its
sector, or every name we cover — plain English, no operators — and answers come back
structured: a summary, the drivers, and a read on each company.
"What did AbbVie say about margins, and did the framing change from last quarter?"
"Did AbbVie's management walk back any full-year guidance, and how did they frame it?"
"Where did AbbVie avoid answering on capital allocation?"
Sentiment analysis on any single earnings call, themes building across a sector, and search
across every company and quarter — each claim linked back to the passage it came from.